官方服务：
资源简介：
Targeting the MTOR-AKT pathway in DLBCL
应用场景：
创建时间：
2012-04-29
相关数据集
Chidamide inhibits double expressor lymphoma through repressing Myc expression and activity. Chidamide inhibits double expressor lymphoma through repressing Myc expression and activity
Double-expressor lymphoma (DEL), defined by MYC and BCL-2 overexpression without corresponding chromosome translocations, is often associated with poor outcomes for standard treatment (R-CHOP). Recent
NIAID Data Ecosystem70
Effect of SRPK1 inhibitor in ENKTL cells
To explore the effect of SRPK1 inhibitor in ENKTL cells
NIAID Data Ecosystem40
ITK Degradation to Block T-cell Receptor Signaling and Overcome Therapeutic Resistance in T-Cell Lymphomas
IL-2-inducible T cell kinase (ITK) is essential for T cell receptor (TCR) signaling and plays an integral role in T-cell proliferation and differentiation. Unlike the ITK homolog BTK, no inhibitors of
NIAID Data Ecosystem30
Table_1_The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines.XLSX
The CD37 targeting radioimmunoconjugate 177Lu-lilotomab satetraxetan (Betalutin) is currently being evaluated in a clinical phase 2b trial for patients with follicular lymphoma (FL) and in a phase 1 t
NIAID Data Ecosystem50
Burkitt Lymphoma Pathogenesis and Therapeutic Targets from Structural and Functional Genomics. Homo sapiens
Burkitt lymphoma (BL) can often be cured by intensive chemotherapy, but the toxicity of such therapy precludes its use in the elderly and in patients with endemic BL (eBL) in developing countries, nec
NIAID Data Ecosystem30
